Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 30.00 | |
10 mg | In stock | $ 47.00 | |
25 mg | In stock | $ 73.00 | |
50 mg | In stock | $ 96.00 | |
100 mg | In stock | $ 142.00 | |
200 mg | In stock | $ 198.00 | |
500 mg | In stock | $ 353.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 50.00 |
Description | Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells. |
Targets&IC50 | UNH:0.3 μM (IC50) |
In vitro | Administration of rabeprazole leads to a marked decrease in the viability of MKN-28 cells. Exposure to rabeprazole induces significant apoptosis in AGS cells. Rabeprazole completely inhibits the phosphorylation of ERK 1/2 in the MKN-28 cells, whereas the same effect is not observed in either the KATO III or MKN-45 cells. Rabeprazole is able to efficaciously inhibit the phosphorylation of ERK 1/2 in the gastric cancer cells.Thus, rabeprazole can attenuate the cell viability of human gastric cancer cells through inactivation of the ERK1/2 signaling pathway[2]. |
In vivo | Rabeprazole does not appear to exacerbate bone metabolic disorders in gastrectomized rats, but rather ameliorates the TG-induced BMD decrease[1]. |
Cell Research | Rabeprazole is administrated to three gastric cancer cell lines, KATO III, MKN-28 and MKN-45, at a dosage of 0.2 mM for 16 h. The viability of these cells is determined by a trypan blue exclusion assay.(Only for Reference) |
Synonyms | Dexrabeprazole Sodium, LY307640 sodium, Habeprazole Sodium, Rebeprazole sodium, Aciphex Sodium |
Molecular Weight | 381.42 |
Formula | C18H20N3NaO3S |
CAS No. | 117976-90-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 71 mg/mL (186.1 mM)
H2O: 1.34mg/mL(3.5mM), Sonification is recommended
Ethanol: 71 mg/mL (186.1 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rabeprazole sodium 117976-90-6 Apoptosis Membrane transporter/Ion channel Proton pump ATPase Dexrabeprazole Sodium LY 307640 ulcerations gastric LY307640 sodium LY307640 UNH Habeprazole Sodium PPI inhibit pump proton Proton Pump reflux uridine Rebeprazole sodium Rabeprazole LY-307640 nucleoside ribohydrolase Inhibitor gastroesophageal Aciphex Sodium inhibitor